HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Deals

M&A, licensing, and major transactions shaping the industry

Novartis Spins Off Sandoz: What the $10B Pure-Play Means for Biosimilar Strategies and Drug Pricing 2025-2026
Deals
Novartis Spins Off Sandoz: What the $10B Pure-Play Means for Biosimilar Strategies and Drug Pricing 2025-2026
With Sandoz now independent and over $10B in revenue, the generics giant faces a high-stakes biosimilars battl…
Apr 7, 2026
Amgen’s $27.8B Horizon Buy: Betting Big on Rare Diseases, Revenue Multiples, and Pipeline Synergies
Deals
Amgen’s $27.8B Horizon Buy: Betting Big on Rare Diseases, Revenue Multiples, and Pipeline Synergies
Amgen’s $27.8B bet on Horizon Therapeutics puts rare disease revenue and high-margin growth at center stage -b…
Feb 27, 2026
The Economics of Pharma Mega-Mergers: Why Most Buyers Overpay
Deals
The Economics of Pharma Mega-Mergers: Why Most Buyers Overpay
AbbVie’s Allergan deal touted $2B in annual savings, but mega-merger math rarely favors acquirers. A close loo…
Jan 19, 2026
CVS Health Splits PBM and Retail: What It Means for Formulary Strategy
Deals
CVS Health Splits PBM and Retail: What It Means for Formulary Strategy
The CVS Health breakup forces Caremark to compete on formulary performance alone, without the retail pharmacy …
Mar 15, 2025
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.